CD8A and neoplasm: Fig. 2D shows that treatment with cisplatin, CpG and PADRE significantly prolongs the survival of TC-1 tumor-bearing mice compared to CD8+ T cell depleted mice and untreated mice. Similarly, depletion of CD4+ T cells significantly impaired the antitumor effects of the triple treatment regimen (S1A Fig.). Furthermore, infusion of PADRE-specific CD4+ T cells into tumor bearing mice significantly enhanced antitumor effect (S1B Fig.).